Details of the CEO of Kangmei Pharmaceutical?

Ma Xingtian, graduated from Macau University of Science and Technology with a major in business administration, was the chairman and general manager of Kangmei Pharmaceutical Co., Ltd. On 2021117, he was sentenced to fixed-term imprisonment 12 years in the first instance for the crimes of not disclosing important information, misappropriating funds and manipulating the securities market. 1997, Kangmei Pharmaceutical was established. From 65438 to 0998, the company successfully developed national new drugs represented by Luo Xinping, Tetra Pak and Nuosha, and was selected as a national science and technology project. March 20001year, led Kangmei Pharmaceutical to be listed on Shanghai Stock Exchange. On June 5438+ 10, 2005, with the support of Kangmei Pharmaceutical, relying on the production base of Chinese herbal medicines, the business scope was continuously expanded, and the largest logistics and distribution center of Chinese herbal medicines in South China was built. In 2009, he was elected as the vice president of the first Council of China Private Enterprise Federation. May 65438+May 2020, resigned as the chairman and general manager of Kangmei Pharmaceutical Co., Ltd. for personal reasons. 2002110/On October 27th, the People's Procuratorate of Foshan City, Guangdong Province prosecuted him for failing to disclose important information, misappropriating funds and manipulating the securities market. On 202 1,1,17, he was sentenced to fixed-term imprisonment of 12 years and fined 65438+200,000 yuan. Kangmei Pharmaceutical Co., Ltd. is referred to as "Kangmei Pharmaceutical" (SSE: 6005 18). 1997 was founded by Mr. Ma Xingtian, a private entrepreneur. The company is located in Puning City, Guangdong Province, formerly known as "Guangdong Kangmei Pharmaceutical Co., Ltd.". Equity restructuring began in 2000. It is one of the large-scale private pharmaceutical enterprises integrating the supply and marketing of medicines, Chinese herbal medicines and medical devices. The company passed the share reform. 201818 on the evening of February 28th, Kangmei Pharmaceutical announced that it had received the notice of filing an investigation by China Securities Regulatory Commission. 20 19 1.2, Kangmei Pharmaceutical Co., Ltd. opened. According to reports, as of 2 10, the company's share price was 8.29 yuan, the daily limit order exceeded 400,000 yuan, and the turnover exceeded 60 million yuan. On April 30th, 20 19, Kangmei Pharmaceutical released nearly 30 billion "accounting errors". An apology letter was sent to shareholders on May 1. 2065438+May 2009 17, China Securities Regulatory Commission informed Kangmei Pharmaceutical that its financial report was fraudulent and was suspected of making false statements and other illegal acts. 2065438+On May 2, 20091day, Kangmei Pharmaceutical Co., Ltd. took the initiative to change its hat to "ST Kangmei".